



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/511,108	10/08/2004	Ruediger Ridder	05033.0006.PCUS00	8587
27194 7590 03/05/2007 HOWREY LLP C/O IP DOCKETING DEPARTMENT 2941 FAIRVIEW PARK DRIVE, SUITE 200 FALLS CHURCH, VA 22042-2924			EXAMINER JOYCE, CATHERINE	
			ART UNIT 1642	PAPER NUMBER
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
31 DAYS		03/05/2007	PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

**Office Action Summary**

Application No.

10/511,108

Applicant(s)

RIDDER ET AL.

Examiner

Catherine M. Joyce

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 08 October 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-26 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-26 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### DETAILED ACTION

1. Claims 1-26 are pending.

### *Election/Restrictions*

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

1. Claims 1-17, 22-24, as drawn to a method for discriminating p16<sup>INK4a</sup> overexpressing metaplasias from p16<sup>INK4a</sup> overexpressing neoplastic lesions in a biological sample in the course of cytological testing procedure comprising (a) determining the presence or absence of cells overexpressing of p16<sup>INK4a</sup> in the biological sample, (b) determining the presence or absence of cells expressing at least one high risk HPV gene-product in the biological sample, *wherein the gene product is a polypeptide*, and (c) assessing simultaneous presence of cells expressing high risk HPV gene-products with cells overexpressing p16<sup>INK4a</sup> or the presence of cells expressing p16<sup>INK4a</sup> alone, wherein the simultaneous presence of cells expressing high risk HPV gene products with cells overexpressing p16<sup>INK4a</sup> is indicative for neoplastic or preneoplastic lesions.
2. Claims 1-15, 17-21, 22-24 as drawn to a method for discriminating p16<sup>INK4a</sup> overexpressing metaplasias from p16<sup>INK4a</sup> overexpressing neoplastic lesions in a biological sample in the course of cytological testing procedure comprising (a) determining the presence or absence of cells

Art Unit: 1642

overexpressing of p16<sup>INK4a</sup> in the biological sample, (b) determining the presence or absence of cells expressing at least one high risk HPV gene-product in the biological sample, *wherein the gene product is a polynucleotide*, and (c) assessing simultaneous presence of cells expressing high risk HPV gene-products with cells overexpressing p16<sup>INK4a</sup> or the presence of cells expressing p16<sup>INK4a</sup> alone, wherein the simultaneous presence of cells expressing high risk HPV gene products with cells overexpressing p16<sup>INK4a</sup> is indicative for neoplastic or preneoplastic lesions.

3. Claims 25 and 26, as drawn to a diagnostic or research kit comprising (a) probes for the detection of presence or absence of the overexpression of p16<sup>INK4a</sup> in biological samples and (b) one or more probes for the detection of the presence or absence of the expression of one or more HPV gene-products in biological samples.

3. The inventions are distinct, each from the other, because of the following reasons:

The inventions listed as Groups 1-3 do not relate to a single inventive concept because they lack the same or corresponding special technical features for the following reasons:

The technical feature linking Groups 1-3 appears to be that they all relate to the use of detection of p16<sup>INK4a</sup> in combination with the detection of an HPV gene product in the detection of cervical neoplasia. However, Agoff et al (2003, Modern Pathology 16(7):665-73) specifically teaches both the use of p16<sup>INK4a</sup> and in combination with the detection of an HPV gene product in the detection of cervical neoplasia. Therefore the technical feature linking the inventions of Groups 1-3 does not constitute a special technical feature as it does not define a contribution over the prior art.

In view of the above, Group 1 is considered the main invention. After that, all

Art Unit: 1642

other products and methods have been broken out as separate groups (see 37 CAR 1.475(d)).

An international stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. When claims to different categories are present in the application, the claims will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories: (1) A product and a process specially adapted for the manufacture of said product; or (2) A product and a process of use of said product; or (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or (4) A process and an apparatus or means specifically designed for carrying out the said process; or (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process. If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application will be considered as the main invention in the claims, see PCT article 17(3) (a) and 1.476 (c), 37 C.F.R. 1.475(b) and (d). Group I will be the main invention. After that, all other products and methods will be broken out as separate groups (see 37 CFR 1.475(d).)

4. Further, the following elections of species are required.

If Groups 1 or 2 are elected, election of specific HPV gene product from the following list is required: E7, E2, E6, L1, L2.

If Groups 1 or 2 are elected, election of specific label from the following list is required: a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, an enzyme.

If Groups 1 or 2 are election, election of probe from the following list is required: a polypeptide; a nucleic acid.

If Group 2 is elected election of a nucleotide detection method from the following list is required: in situ hybridization; a nucleic acid amplification reaction.

If a nucleic amplification reaction above is elected election of a specific reaction type from the following list is required: LCR or PCR.

If Groups 1 or 2 are elected, election of a specific HPV subtype from the following list is required: 16, 18, 31, 33, 35, 39, 39, 45, 51, 52, 56, 58.

5. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 809.02(a).

6. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103 of the other invention.

7. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103.

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1642


9. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catherine M. Joyce whose telephone number is 571-272-3321. The examiner can normally be reached on Monday thru Friday, 10:15 - 6:45.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley, can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8700.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SEARCHED, PAID  
INDEXED, FILED



Catherine M. Joyce  
Examiner  
Art Unit 1642